World Health Organisation forces FDA to suspend Tobinco’s medicines

The FDA has suspended operations at Entrance Pharmaceutical and Research Centre, a Tobinco Pharmaceuticals Ltd facility, due to serious violations of WHO Good Manufacturing Practices.

An inspection revealed critical safety and quality issues, prompting the FDA to order a halt in production and demand a Corrective and Preventive Action Report.

This suspension follows a GH¢94 million judgment debt awarded to Tobinco over the destruction of unexpired drugs.

The FDA maintains that its actions are in line with legal standards to protect public health.